ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) study: safety, toxicity and immunological effects of peritumorally delivered immunotherapy in early-stage cervical cancer
The ITHACA study is exploring a new approach to treating early cervical cancer. This research focuses on a special type of treatment called immunotherapy, which helps your body's immune system fight cancer cells. Instead of being given through a drip or as a pill, this treatment is delivered directly into or very close to the tumour in the cervix. The main goals of this early-stage study are to check if this new way of giving the medicine is safe, to understand any side effects it might have, and to see how it affects your immune system. It's an important step in finding better treatments for cervical cancer.
At a glance
What is this study about?
The ITHACA study is an important piece of research looking into how we can improve treatments for early cervical cancer. Cervical cancer is a type of cancer that starts in the cervix, which is the lower part of the womb. At the moment, treatments for early cervical cancer often involve surgery, radiotherapy, or chemotherapy. This study is exploring a new kind of treatment called immunotherapy. Immunotherapy works by helping your body's own defence system, called the immune system, recognise and fight off cancer cells more effectively. Think of it as giving your body's natural protectors a boost to do their job better.
What makes this study special is how the immunotherapy is given. Instead of a general treatment that goes all over your body, this medicine is carefully delivered directly into, or very close to, your tumour in the cervix. The idea behind this is to target the cancer more precisely and hopefully reduce side effects in other parts of your body. This is an early-stage study, meaning it's one of the first times this specific approach is being tested in people. Because it's an early study, the main things the researchers want to find out are whether this treatment is safe, what side effects it might cause, and how it affects your body’s immune system around the tumour.
By taking part in studies like ITHACA, patients contribute to our understanding of cancer and help develop potentially more effective and gentler treatments for the future. Every step in research brings us closer to better care, and this study aims to explore a promising new path for women with early cervical cancer.
Key takeaways
- This study explores a new way to treat early cervical cancer.
- It uses immunotherapy, which boosts your body's own defence system.
- The treatment is given directly into or around the tumour.
- The main focus is to check if the treatment is safe and how it affects the body.
- It's an early-stage study, helping us learn for the future.
- Participation contributes to new medical knowledge for cervical cancer.
Who may be eligible?
To join the ITHACA study, there are some specific requirements to make sure the study is right for you and that the results are clear. This study is looking for women who have been diagnosed with early-stage cervical cancer. It’s important that your cancer hasn’t spread far from your cervix.
You also need to be at least 18 years old. There isn't an upper age limit mentioned, so doctors will consider all adult women if they meet the other study requirements and are generally well enough to take part.
Before you can join, the study doctors will review your medical history, recent test results, and overall health to make sure that taking part is safe for you and that you fit all the necessary criteria for the research.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you an adult woman (18 years or older)?
- Have you been diagnosed with early-stage cervical cancer?
- Has your doctor confirmed your cancer has not spread extensively?
- Are you generally well and able to consider new treatments?
What does participation involve?
If you decide to take part in the ITHACA study, you would first have a full medical check-up, including blood tests and scans, to confirm you meet all the study requirements. The immunotherapy treatment would then be given directly into or very close to your cervical tumour, likely requiring a procedure under local or general anaesthetic. You would also have regular follow-up appointments, which would include more blood tests, physical examinations, and possibly further scans or biopsies to check how you are responding to the treatment and to monitor any side effects. The exact number and frequency of visits, as well as the total duration of your participation, would be clearly explained by the study team before you join.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is immunotherapy?
Immunotherapy is a treatment that helps your body's own immune system fight cancer cells more effectively.
How is this treatment given?
The medicine is injected directly into or very close to the cervical tumour, rather than through a drip or as a pill.
What are the main goals of this study?
The study aims to check if this new treatment method is safe, what side effects it has, and how it affects your body's immune system.
What kind of cervical cancer is this for?
This study is for women with early-stage cervical cancer.
Will this treatment cure my cancer?
This is an early-stage study, and while it aims to find better treatments, no treatment can guarantee a cure. It's about gathering information on safety and effects.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.